The Central and Eastern European Gynecologic Oncology Group
Quick facts
Marketed products
- antibiotic prophylaxis · Infectious Disease Prevention / Surgical Prophylaxis
Antibiotic prophylaxis prevents surgical site infections by eliminating bacteria before they can establish infection at the surgical wound. - Antibiotics administration · Infectious Disease / Supportive Care in Oncology
Antibiotics kill or inhibit bacterial pathogens by targeting bacterial cell wall synthesis, protein synthesis, or DNA replication.
Phase 3 pipeline
- Antenatal steroids administration · Obstetrics/Neonatology
Antenatal steroids (typically corticosteroids like betamethasone or dexamethasone) accelerate fetal lung maturity by promoting surfactant production, reducing respiratory distress syndrome risk in preterm infants. - Neuroprotection · Neuroscience
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- The Central and Eastern European Gynecologic Oncology Group portfolio CI brief
- The Central and Eastern European Gynecologic Oncology Group pipeline updates RSS
Frequently asked questions about The Central and Eastern European Gynecologic Oncology Group
What are The Central and Eastern European Gynecologic Oncology Group's marketed drugs?
Top marketed products include antibiotic prophylaxis, Antibiotics administration.
What is The Central and Eastern European Gynecologic Oncology Group's pipeline?
The Central and Eastern European Gynecologic Oncology Group has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Antenatal steroids administration, Neuroprotection.
Related
- antibiotic prophylaxis · Infectious Disease Prevention / Surgical Prophylaxis
- Antibiotics administration · Infectious Disease / Supportive Care in Oncology
- Sector hub: All tracked pharma companies